MENU
+Compare
FATE
Stock ticker: NASDAQ
AS OF
Sep 18, 04:59 PM (EDT)
Price
$1.00
Change
+$0.05 (+5.26%)
Capitalization
109.64M

FATE Fate Therapeutics Forecast, Technical & Fundamental Analysis

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States... Show more

Industry: #Biotechnology
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for FATE with price predictions
Sep 17, 2025

Momentum Indicator for FATE turns negative, indicating new downward trend

FATE saw its Momentum Indicator move below the 0 level on August 29, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In of the 91 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for FATE turned negative on September 02, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 60 similar instances when the indicator turned negative. In of the 60 cases the stock turned lower in the days that followed. This puts the odds of success at .

FATE moved below its 50-day moving average on August 25, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for FATE crossed bearishly below the 50-day moving average on August 29, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FATE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FATE's RSI Oscillator exited the oversold zone, of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FATE advanced for three days, in of 248 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.419) is normal, around the industry mean (19.637). P/E Ratio (0.000) is within average values for comparable stocks, (53.583). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.168). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (13.263) is also within normal values, averaging (331.570).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. FATE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

FATE is expected to report earnings to rise 5.10% to -30 cents per share on October 30

Fate Therapeutics FATE Stock Earnings Reports
Q3'25
Est.
$-0.30
Q2'25
Beat
by $0.05
Q1'25
Beat
by $0.07
Q4'24
Est.
$-0.44
Q3'24
Beat
by $0.02
The last earnings report on August 12 showed earnings per share of -28 cents, beating the estimate of -34 cents. With 1.02M shares outstanding, the current market capitalization sits at 109.64M.
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12278 Scripps Summit Drive
Phone
+1 858 875-1800
Employees
220
Web
https://www.fatetherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IFPJF12.510.86
+7.38%
Informa Plc.
PBKOF14.800.53
+3.73%
Pollard Banknote Ltd.
TLTFF0.14N/A
+1.19%
Theralase Technologies Inc.
ANSLF20.02N/A
N/A
Ansell Ltd.
BINP0.03N/A
N/A
Bionoid Pharma Inc.

FATE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with RXRX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-0.07%
RXRX - FATE
53%
Loosely correlated
-2.58%
ALLO - FATE
53%
Loosely correlated
-4.24%
CRBU - FATE
53%
Loosely correlated
-4.17%
MGNX - FATE
51%
Loosely correlated
+4.08%
IPSC - FATE
50%
Loosely correlated
+1.37%
More